NCT05704049 2025-12-29
IZALCO
Sanofi
Phase 2 Active not recruiting
Clinical Trials
11 trialsNCT02294357 2023-11-01
Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib
Oncotherapeutics
Phase 2 Terminated
NCT02229136 2022-12-01
Miracle Mouthwash Plus Hydrocortisone vs Prednisolone Mouth Rinse for Mouth Sores Caused by Everolimus
US Oncology Research
Phase 2 Completed
NCT00136903 2022-01-31
Safety and Efficacy Study of Adult Human Mesenchymal Stem Cells to Treat Acute Graft Versus Host Disease (GVHD)
Mesoblast, Ltd.
Phase 2 Completed
NCT02953678 2021-11-24
A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1)
Incyte Corporation
Phase 2 Completed
NCT02962284 2021-11-19
One-year, Open Extension to Evaluate the Treatment of Patients With Castration-Resistant Prostate Cancer With YONSAâ„¢
Sun Pharmaceutical Industries Limited
Phase 2 Completed
NCT02763761 2018-10-09
An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or Opdivo
Bristol-Myers Squibb
Phase 2 Withdrawn
NCT01985126 2018-06-25
An Efficacy and Safety Study of Daratumumab in Patients With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor [PI] and Immunomodulatory Drug [IMiD]) or Are Double Refractory to a PI and an IMiD
Janssen Research & Development, LLC
Phase 2 Completed
NCT00574288 2018-04-27
Daratumumab (HuMax®-CD38) Safety Study in Multiple Myeloma
Janssen Research & Development, LLC
Phase 2 Completed
NCT00332696 2011-09-23
Octreotide Compared to Placebo in Patients With Inoperable Bowel Obstruction Due to Peritoneal Carcinomatosis
Novartis
Phase 2 Completed
NCT00676832 2010-09-29
Study of COLAL-PRED to Treat Moderate to Severe Ulcerative Colitis
Prometheus Laboratories
Phase 2 Completed